Market Overview - The Hang Seng Index and the National Enterprises Index fell by 4.0% and 3.7% respectively last week, primarily due to tariff issues and concerns surrounding U.S. regional banks Zions and Western Alliance involved in credit fraud cases [1] - On Friday, the Hang Seng Index and the National Enterprises Index dropped by 2.5% and 2.7% respectively, with major sectors like technology, healthcare, brokerage, and automotive seeing significant declines, while gold-related stocks like Lao Pu Gold and Chow Tai Fook rose due to increasing gold prices [1] Company Performance - Chow Tai Fook reported a recovery in same-store sales growth in mainland China, Hong Kong, and Macau for Q2 (July-September), with retail value increasing by 4.1% year-on-year [1] - Insurance companies, including China Pacific Insurance and China Life, released positive profit forecasts, expecting net profit growth of 40%-60% and 50%-70% respectively for the first three quarters [2] Macroeconomic Dynamics - The Eurozone's harmonized consumer price index (CPI) for September showed a year-on-year increase of 2.2%, up 0.2 percentage points from August, aligning with Bloomberg's forecast [3] - Core consumer prices, excluding food and energy, rose by 2.4% year-on-year, exceeding both August's figures and Bloomberg's predictions by 0.1 percentage points [3] Industry Dynamics - In the gaming sector, Macau's gaming revenue for Q3 reached 62.57 billion MOP, reflecting a year-on-year increase of 12.5% and a quarter-on-quarter increase of 2.4% [4] - Despite a general decline in Hong Kong stocks due to fluctuations in U.S.-China trade relations, new consumer stocks like Lao Pu Gold performed well, rising by 18.0% last week [4] - In the automotive sector, NIO responded to GIC's allegations, stating that the related unfounded claims were investigated three years ago, with its stock rebounding by 2.1% on Friday after a 12.9% decline over the week [4] Pharmaceutical Sector - The pharmaceutical industry saw a general decline last week, influenced by U.S. Senate discussions on banning certain Chinese biotech companies from receiving federal funding and President Trump's remarks on lowering prices for popular diabetes and weight loss drugs [5] - Despite these challenges, Chinese pharmaceutical companies have made significant progress in overseas licensing, with Hansoh Pharmaceutical granting Roche rights to develop and commercialize a colorectal cancer drug outside of mainland China and Hong Kong, receiving an upfront payment of $80 million and potential milestone payments of up to $1.45 billion [5] New Energy and Utilities - The new energy and utilities sector in Hong Kong experienced a general decline, although defensive stocks like Huaneng International, China Everbright Environment, and Power Assets Holdings saw gains of 3.9%, 6.6%, and 2.1% respectively [6] - The photovoltaic sector faced notable declines, with companies like Xinyi Solar, Flat Glass Group, and GCL-Poly Energy dropping by 4.5%, 3.9%, and 0.8% respectively [6]

Group 1: Overall Industry Insights - The overall tourism demand remained robust during the recent Golden Week, with positive growth in Average Daily Rate (ADR) and Revenue per Available Room (RevPAR) for hotels, showing a mid to high single-digit growth in the industry [1] - Experts predict that the increase in hotel franchise supply will continue to exert pressure, particularly in the mid to high-end market segment [1] - The competition among online travel platforms is moderate, as smaller or newly entered operators lack supply chain and scale advantages, limiting their competition to specific niche areas [1] Group 2: Company Preferences - The company remains optimistic about the hotel sector, particularly for Huazhu Group (01179, HTHT.US) and Atour (ATAT.US), anticipating that the slowdown in competition from online travel platforms and hotel supply growth will lead to continued improvement in RevPAR [1] - The Macau gaming industry is expected to benefit from wealth effects and a low base of total gaming revenue, with a favorable outlook for Sands China (01928) and Galaxy Entertainment (00027) [1] - The company suggests buying Ctrip Group (09961, TCOM.US) and Air China (601111) (00753, 601111.SH), as both are expected to benefit from recent long-haul outbound travel demand and better-than-expected ticket prices [1]

Group 1 - The overall tourism demand remained robust during the recent Golden Week, with positive growth in average daily room rates (ADR) and revenue per available room (RevPar) for hotels, showing a mid to high single-digit growth in the industry [1] - Experts anticipate that the increase in hotel franchise supply will continue to exert pressure, particularly in the mid to high-end market segment [1] - The competition among online travel platforms is moderate, as smaller or newly entered operators lack supply chain and scale advantages, limiting their competition to specific niche areas [1] Group 2 - The company remains optimistic about the hotel sector, particularly for Huazhu Group and Atour, expecting continued improvement in revenue per available room due to a slowdown in competition from online travel platforms and hotel supply growth [1] - The Macau gaming industry is expected to benefit from wealth effects and a low base of total gaming revenue, with a favorable outlook for Sands China and Galaxy Entertainment [1] - The company recommends buying shares in Trip.com Group and China Southern Airlines, as both are expected to benefit from recent long-haul outbound travel demand and better-than-expected ticket prices [1]

Core Insights - Overall tourism demand remained robust during the recent Golden Week, with positive growth in average daily room rates (ADR) and revenue per available room (RevPAR) for hotels, showing a mid to high single-digit percentage increase [1] - The supply pressure from increasing hotel franchises, particularly in the mid to high-end market, is expected to continue [1] - Online travel platforms face moderate competition, as smaller or newer operators lack supply chain and scale advantages, limiting their competitiveness to specific niches [1] Industry Preferences - The hotel sector is favored, with companies like Huazhu Group and Atour expected to benefit from a slowdown in competition from online travel platforms and hotel supply growth, leading to improved revenue per available room [1] - The Macau gaming industry is viewed positively due to wealth effects and a low base of total gaming revenue, with companies like Sands China and Galaxy Entertainment being highlighted [1] - Ctrip and China Southern Airlines are recommended for purchase, benefiting from recent long-haul outbound travel demand and better-than-expected ticket prices [1]

Group 1 - The gaming stocks experienced a collective rise, indicating positive market sentiment in the sector [1] - Sands China (01928.HK) increased by 5.04%, reaching HKD 18.98 [1] - Wynn Macau (01128.HK) rose by 4.6%, trading at HKD 6.59 [1] - Melco International Development (00200.HK) saw a gain of 4.45%, priced at HKD 4.69 [1] - Galaxy Entertainment (00027.HK) climbed by 3.94%, with a share price of HKD 38.48 [1]

Core Insights - The gaming stocks have collectively risen, with Sands China up 5.04%, Wynn Macau up 4.6%, Melco International Development up 4.45%, and Galaxy Entertainment up 3.94% [1] Industry Summary - CICC maintains its forecast for total gaming revenue in Macau for 2025 while raising the forecast for 2026, expecting a year-on-year growth of 9% and 5% respectively, recovering to 84% and 88% of 2019 levels [1] - The brokerage anticipates mass gaming revenue to grow by 7% and 6% in the next two years, reaching 119% and 126% of 2019 levels [1] - VIP gaming revenue is projected to increase by 19% in 2025 but decrease by 5% in 2026, recovering to 29% and 28% of 2019 levels [1] Company Insights - Huatai Securities notes that despite temporary disruptions from typhoons during the National Day holiday and late September, the number of visitors to Macau has met government expectations and exceeded levels from the same period in 2019 when excluding weather impacts [1] - The daily gaming revenue during the National Day holiday showed a slight year-on-year increase [1] - Key drivers for the sector post-holiday include policies like "one permit, multiple entries" between Zhuhai and Macau, the wealth effect from "gold stocks," and the synergistic effects of non-gaming events such as the NBA China Games and the National Games [1]

Group 1 - The stock of Wynn Macau (01128.HK) increased by nearly 4% on October 20, reaching a price of 6.54 HKD per share [1] - As of the report, the stock was up 3.81% with a trading volume of 30.22 million HKD [1]

Investment Rating - The report indicates a positive outlook for the overseas pharmaceutical industry, particularly focusing on innovative drugs and clinical trial advancements [11]. Core Insights - The report highlights significant clinical trial updates from various companies, including Innovent Biologics, CanSino Biologics, and Kelun-Biotech, with a focus on their ongoing studies for advanced cancer treatments [6][7][8]. - The report emphasizes the successful third-phase clinical trials for several drugs, including TUKYSA for HER2+ metastatic breast cancer, and the acquisition of Orbital Therapeutics by BMS for $1.5 billion, indicating strong market activity and investment in innovative therapies [9][10]. Summary by Sections 1. Overseas Pharmaceuticals - The report discusses the recent updates from the 2025 ESMO conference, including multiple clinical trials for drugs targeting advanced kidney cancer and non-small cell lung cancer [6][7]. - Notable companies mentioned include Innovent Biologics with its study on IBI363 for sq-NSCLC, and Kelun-Biotech's TROP2 ADC for EGFR mutation-positive NSCLC [8][9]. 2. Market Performance - The Hang Seng Healthcare Index experienced a decline of 5.01%, underperforming the Hang Seng Index by 1.78 percentage points [6]. - The report notes the overall positive growth in the pharmaceutical sector, driven by innovative drug commercialization and active mergers and acquisitions [11]. 3. Company Updates - BMS's acquisition of Orbital Therapeutics for $1.5 billion is highlighted, showcasing the trend of consolidation in the pharmaceutical industry [9]. - Strong quarterly performance from Johnson & Johnson and Pfizer is reported, with J&J achieving $23.993 billion in revenue, a 6.8% year-over-year increase [10]. 4. Recommendations - The report suggests focusing on innovative drug companies with active clinical pipelines, including Innovent Biologics, CanSino Biologics, and Kelun-Biotech, as potential investment opportunities [11].

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector [1]. Core Insights - The report highlights key clinical data updates from the 2025 ESMO conference, focusing on several companies including Innovent Biologics, CanSino Biologics, and Kelun-Biotech, which are conducting pivotal clinical trials for various cancer treatments [1][7]. - Notable advancements include the registration studies for IBI363 by Innovent Biologics and the approval of a third indication for TROP2 ADC by Kelun-Biotech, showcasing the ongoing innovation in the sector [8][9]. - The report emphasizes the strong performance of companies like BMS and Pfizer, with BMS acquiring Orbital Therapeutics for $1.5 billion and Pfizer reporting positive results from its HER2 inhibitor trial [9][10]. Summary by Sections 1. Overseas Pharmaceuticals - The Hang Seng Healthcare Index fell by 5.01%, underperforming the Hang Seng Index by 1.78 percentage points [6]. - Key events include multiple clinical trials presented at the 2025 ESMO, such as Innovent's study on the combination of sintilimab and lenvatinib for advanced renal cell carcinoma [7]. - The report suggests continued monitoring of innovative drugs and clinical progress from companies like BeiGene, Innovent, and CanSino [11]. 2. Company Updates - BMS announced a $1.5 billion acquisition of Orbital Therapeutics, which includes the OTX-201 therapy [9]. - Strong performance reported by Johnson & Johnson with Q3 2025 revenue of $23.993 billion, a 6.8% year-over-year increase [9]. - Pfizer's TUKYSA trial for HER2+ metastatic breast cancer yielded positive top-line results, indicating a successful phase in their drug development [10]. 3. Market Trends - The report notes a significant increase in inbound tourism to Macau during the National Day holiday, with a total of approximately 1.14 million visitors, marking a 1.9% year-over-year growth [13]. - The average daily visitor count reached a record high of 143,000, reflecting a recovery in the tourism sector [13].

Group 1 - The core viewpoint of the article indicates a general decline in gaming stocks, with specific companies experiencing notable drops in share prices [1] - According to HSBC Global Research, Macau's total gaming revenue (GGR) for the first 12 days of October was 9.65 billion MOP, with an average daily revenue of 593 million MOP in the second week, reflecting a year-on-year decline of 8% and a week-on-week decline of 46%, which is higher than the historical average decline of 39% [1] - Citigroup has revised its forecast for October's total gaming revenue down from 23 billion MOP to 22 billion MOP, which is approximately 83% of October 2019 levels and represents a year-on-year increase of 6% [1] Group 2 - The slowdown in overall gaming revenue growth in Macau suggests limited short-term upside potential for gaming stocks, despite potential support from a low base in December for Q4 revenue growth [1] - Specific declines in stock prices include Melco International Development down 3.21% to 4.53 HKD, Suncity Group Holdings down 2.56% to 0.76 HKD, Sands China down 1.65% to 17.93 HKD, and Wynn Macau down 1.56% to 6.3 HKD [1]